Skip to main content

Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials

The data bolsters Eli Lilly's position in the budding weight loss drug market and establishes the company as a formidable competitor to Novo Nordisk.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.